Revenue from operations increased 17.5% year-on-year to ₹2,545 crore in Q1 FY27 from ₹2,166.7 crore in Q1 FY26.
Earnings before interest, taxes, depreciation and amortisation (EBITDA) rose 9.5% to ₹537.1 crore, compared with ₹490.7 crore in the year-ago quarter. EBITDA margin stood at 21.1% in the quarter, compared with 22.6% in Q1 FY26.
Hospital business revenue rises 19%
Fortis Healthcare’s hospital business reported revenue of ₹2,187 crore in Q1 FY27, up 19% year-on-year. Operating EBITDA margin for the hospital business stood at 21.5%, compared with 22.1% in the corresponding quarter last year.
The company said hospital business growth during the quarter was driven by a moderate increase in average revenue per occupied bed (ARPOB) and a 16.7% increase in occupied beds compared with Q1 FY26.
The quarterly performance included contributions from recent acquisitions, primarily new hospital acquisitions in Punjab and Bengaluru, along with the leased facility in Delhi-NCR.
Fortis said excluding the impact of these facilities, operating EBITDA margins on a like-for-like basis were similar to Q1 FY26 at 22%.
Fortis enters Odisha with Cuttack hospital agreement
During the quarter, Fortis Healthcare entered into an operations and management agreement for a 300-bed greenfield multi-specialty hospital to be constructed in Cuttack, marking the company’s entry into Odisha.
The company said it plans to pursue similar arrangements, including operations and management contracts, healthcare services agreements and direct lease arrangements.
ALSO READ | Fortis Healthcare shares gain as analysts see up to 25% upside post solid Q3
Fortis said its focus would be on opportunities in dense catchment areas in key clusters such as Delhi-NCR to further strengthen its presence in select micro-markets.
Company plans capacity addition of 1,800 beds
Fortis Healthcare said its ongoing brownfield expansion plans are expected to add around 1,800 beds over the next four to five years. The company said the consolidated business, including hospital and diagnostics segments, is expected to achieve revenue growth in line with market growth over this period.
Fortis said an expanded bed base, higher operating leverage and a robust medical programme mix are expected to support gradual improvement in operating EBITDA margins to the mid-twenties over the next few years.
Net debt rises to ₹2,233 crore
Fortis Healthcare’s net debt stood at ₹2,233 crore as of June 30, 2026. Net debt to EBITDA was at 1.01 times, compared with 0.92 times as of June 30, 2025, based on Q1 annualised EBITDA. Net debt to equity stood at 0.21 times as of June 30, 2026, compared with 0.20 times a year earlier.
Diagnostics business expands network
In the diagnostics business, Fortis said Agilus continued its network expansion strategy, primarily through the addition of new customer touch points (CTPs). The total number of customer touch points stood at 4,493 as of June 30, 2026.
ALSO READ | Fortis Healthcare Q3 profit falls despite strong revenue growth; Hospital biz up 14%
Agilus conducted around 10.46 million tests in Q1 FY27, compared with around 10.13 million tests in Q1 FY26. The preventive portfolio revenue in Agilus grew 27% year-on-year during the quarter, while specialised portfolio revenue increased 13% compared with the corresponding period last year.
Dr Ashutosh Raghuvanshi, MD and CEO, Fortis Healthcare, stated, “Building on the momentum of the previous year, we have made a positive start to the financial year, delivering a steady Q1 performance across both our hospital and diagnostics businesses. We recently entered into an O&M agreement for a 300-bedded greenfield multi-specialty hospital to be developed in Cuttack.
This marks Fortis Healthcare’s entry into Odisha, further expanding our presence in growth markets. Our recent acquisitions in our focus geographies are ramping up well. We also continued to invest in our medical
infrastructure by expanding our robotic systems across key facilities, reinforcing our commitment to clinical excellence and technology-led care.”
He further added, “The diagnostics business also witnessed a steady revenue growth along with an improvement in EBITDA margins compared to the corresponding period of the previous year. We remain focused on delivering sustained growth across both our businesses over the remaining quarters of the financial year, supported by our expansion plans, strategic growth initiatives and a continued focus on operational excellence.”
ALSO READ | Fortis Healthcare shares have 33% upside potential on strong earnings visibility: Citi
Shares of Fortis Healthcare Ltd ended at ₹935.00, up by ₹9.40, or 1.02%, on the BSE.
